logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Progenics: The FDA Accepted the NDA for Its Cancer Product Azedra® and Granted It Priority Review

Progenics Pharmaceuticals (PGNX)  has good news today. The U.S. Food and Drug Administration (FDA) has accepted for review the firm’s New Drug Application (NDA) for its product  Azedra®  for recurrent and/or unresectable  pheochromocytoma and paraganglioma  — rare neuroendocrine tumors. The FDA has also granted...

Read More

December 28, 2017

0

Regeneron’s and Bluebird Bio’s collaboration is meant to create advanced immune cell therapy

Regeneron Pharmaceuticals (REGN) and   bluebird bio, Inc. (BLUE) announced a collaboration to apply their respective technology platforms to the discovery, development, and commercialization of novel immune cell therapies for cancer . The collaborators will specifically leverage Regeneron’s   VelociSuite ®  platform...

Read More

August 9, 2018

0

Aerie’s successful new confirmatory study for Rhopressa® was a necessity

Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of its glaucoma product Rhopressa ®  (netarsudil ophthalmic solution ) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. This...

Read More

August 15, 2018

0

Why Celyad’s stock gained $2.30 today

Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including  solid tumors.  Celyad announced its consolidated financial results for the six-month period ending 30 June 2018. Celyad’s report is endorsed by Europe. Dr. Christian Homsy, Celyad’s...

Read More

August 23, 2018

0

More Exciting News for Sangamo

Sangamo’s (SGMO)  has abundant positive news since it offered proof of concept and feasibility of its zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation approach and other approaches. The most recent announcement was made early today by Sangamo and  Pfizer...

Read More

January 3, 2018

0

When all the prophets are taken by surprise

When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The revolution in the biotech sector has proven to be moving fast towards reaching goals that were impossible to imagine a couple of years ago...

Read More

August 24, 2018

0

Exelixis Strategy: Expanding the Pipeline with Novel Products

As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially available compounds, cabozantinib and cobimetinib,   Exelixis (EXEL)   entered into an exclusive collaboration and license agreement with  StemSynergy Therapeutics .  The aim of...

Read More

January 8, 2018

0

Juno Therapeutics’ Stock Rally. Exelixis’ Successful Trial for Liver Cancer

Juno Therapeutics’ (JUNO)   stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street journal report stating that Celgene (CELG) was in discussions to take over Juno and that the negotiations could result in a deal...

Read More

January 17, 2018

0

PTC Therapeutics now with a wealthier pipeline

Before we sell PTC Therapeutics (PTCT) , after the stock had reached and surpassed our latest and highest 2018 target, the firm did the right thing that we expected was good enough to encourage investment in this firm.  The good...

Read More

August 28, 2018

0

The FDA Grants Breakthrough Therapy Designation for Balovaptan – Roche’s Product for Autism Spectrum Disorder (ASD)

Yes, the title is real and correct and the condition is ASD. The US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for  Roche’s (RHHBY)   drug balovaptan developed for  ASD.  Balovaptan has shown the potential to ...

Read More

January 30, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 43
  • 44
  • 45
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy